ClinicalTrials.gg
CompletedNCT05087030Updated Oct 24, 2024Results posted

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

A Phase 3 interventional study of RGB-14-P and Prolia® in Postmenopausal Osteoporosis, sponsored by Gedeon Richter Plc.. Completed at 59 sites in 8 countries. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Gedeon Richter Plc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
473
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Osteoporosis, Postmenopausal with a site in Poland — none open to participants now, 2 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · Poland.

Enrollment
23rd of 36
473 · median 543
Started
2021
with 2 others
Phase 3
27 of 36
none open now
Registered
30th of 36
by date
Lead sponsor
1 of 36
Gedeon Richter Plc.

Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, this one is the 23rd largest by enrollment, is one of 3 that started in 2021, is one of 27 in phase 3, and was the 30th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

None of the 36 studies in Osteoporosis, Postmenopausal with a site in Poland is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 60 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Osteoporosis, Postmenopausal with a site in Poland as a file.
02

Study summary

This study will be conducted to assess the efficacy, pharmacodynamic (PD), safety, tolerability, and immunogenicity of RGB -14- P compared to US-licensed Prolia® in participants with postmenopausal osteoporosis, in a comparative manner.

Read the detailed description

This is a randomized, double-blind, multicentre, multiple fixed-dose, 2-arm parallel-group study that includes 2 periods as:

  1. Main period (52 weeks), consists of Treatment Period 1 (26 weeks) and Treatment Period 2 (26 weeks). On Day 1 of Treatment Period 1, prior to dosing, participants will be randomized in a 1:1 ratio to receive either RGB-14-P or Prolia®.
  2. Transition Period: consists of Treatment Period 3 (26 weeks). On Day 1 of Treatment Period 3 (Week 52), a subset of participants who received Prolia® during the Main Period will be re-randomized 1:1 to receive either a dose RGB-14-P or Prolia® in a double-blinded manner. A subset of participants continuing in the Transition Period who received RGB-14-P during the Main Period will continue to receive a dose of RGB-14- P but will also follow the randomization procedure to maintain blinding.

All participants will receive the study drugs on 2 occasions (Weeks 0 and 26), on Day 1 of Treatment Periods 1 and 2. Participants continuing to the Transition Period will receive the study drugs on a third-occasion (Week 52), Day 1 of Treatment Period 3. One Treatment Period will take 6 months (26 weeks, 183 days).

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Biosimilars
  • Prolia®
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is an ambulatory woman, diagnosed with osteoporosis, able to walk, and not bedridden
  • Participant has an absolute BMD consistent with T score ≤ 2.5 and ≥ 4.0 at the lumbar spine as measured by dual-energy X-ray absorptiometry (DXA) during the Screening Period and at least 2 lumbar vertebrae (from L1 to L4) must be evaluable by DXA
  • Participant has body weight ≥ 50 and ≤ 90 kg at the Screening Period

Participants must meet the following criteria to be enrolled in the Transition Period:

  • Have been enrolled, received both doses of the test drug, and completed the scheduled Main Period (up to Week 52) of the RGB-14-101 study

Exclusion criteria

Exclusion Criteria:

  • Participant has a history and/or presence of a severe or more than two moderate vertebral fractures as determined by central reading of lateral spine X-ray during the Screening Period
  • Participant has a history and/or presence of hip fracture
  • Participant has a history and/or presence of atypical femur fracture
  • Participant presents with an active healing fracture
  • Participant has a bilateral hip replacement (unilateral is allowed if the other hip is evaluable with DXA)
  • Participant has a vitamin D deficiency
  • Participant has hypocalcaemia or hypercalcemia at the Screening Period
  • Participant has a history and/or presence of bone , renal osteodystrophy, osteomyelitis, any metabolic, endocrine or traumatic bone disease
  • Participant has a current uncontrolled status of hypothyroidism or hyperthyroidism
  • Participant has a history (within 5 years prior to Screening) and/or current hypoparathyroidism or hyperparathyroidism
  • Participant has within 5 years before Screening
  • Participant has a history and/or presence of significant cardiac disease
  • Participant has a known intolerance or malabsorption of calcium or vitamin D supplements
  • Participant shows to denosumab therapy (e.g., hypocalcaemia), or calcium or vitamin D supplementation before starting test drug administration
  • Participant has a latex allergy
  • Participant has a history and/or presence of osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures
  • Participant has history and/or presence of osteonecrosis of the external auditory canal
  • Participant requiring ongoing use of any osteoporosis treatment
  • Participant has previously received denosumab or biosimilar denosumab
  • Participant has weight or girth measurements which may preclude accurate DXA measurements
  • Participant has an active infection, including, but not limited to severe acute respiratory syndrome coronavirus-2, hepatis B, and infections during the Screening Period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
473 participants (actual)

Study arms

  • Experimental
    RGB-14-P (Main period)

    Randomized participants will receive subcutaneous (SC) injection of RGB-14-P, on Day 1 of Treatment periods 1 and 2.

    Drug: RGB-14-P

  • Active comparator
    Prolia® (Main period)

    Randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment periods 1 and 2.

    Drug: Prolia®

  • Experimental
    RGB-14-P (Transition period)

    Re-randomized participants will receive SC injection of RGB-14-P, on Day 1 of Treatment period 3.

    Drug: RGB-14-P

  • Active comparator
    Prolia® (Transition period)

    Re-randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment period 3.

    Drug: Prolia®

  • Experimental
    RGB-14-P (Continued till transition period)

    Randomized participants will continue to receive SC injection of RGB-14-P from the main period till Day 1 of Treatment period 3.

    Drug: RGB-14-P

Interventions

  • DrugRGB-14-P

    Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.

  • DrugDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD)

    Percentage change from baseline in lumbar bone BMD was assessed. BMD at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). This outcome measure was assessed for main period.

    Time frame: Week 52

  2. Area Under the Effective Curve (AUEC) After the First Dose Until Day 183 of %CfB in Serum Type I Collagen C-telopeptide (sCTX)

    The AUEC of %CfB in sCTX of RGB-14-P was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants was demonstrated with postmenopausal osteoporosis. This outcome measure was assessed for main period only.

    Time frame: Week 26

Secondary outcomes

  1. %CfB in Total Hip BMD

    %CfB in total hip BMD was assessed.

    Time frame: Weeks 26, 52 and 78

  2. %CfB in Lumbar Spine BMD

    %CfB in lumbar spine BMD was assessed.

    Time frame: Weeks 26 and 78

  3. %CfB in Femoral Neck BMD

    %CfB in femoral neck BMD was assessed by DXA.

    Time frame: Weeks 26, 52 and 78

  4. Number of Participants With Vertebral Fragility Fracture

    Number of participants with vertebral fragility fracture was assessed. Information on vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.

    Time frame: Weeks 52 and 78

  5. Number of Participants With Non-vertebral Fragility Fracture

    Number of participants with non-vertebral fragility fracture was assessed. Information on non-vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.

    Time frame: Weeks 52 and 78

  6. %CfB in Serum Procollagen Type 1 N Terminal Propeptide (P1NP)

    %CfB in serum P1NP was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants with postmenopausal osteoporosis.

    Time frame: Weeks 4, 26, 52 and 78

  7. %CfB in Serum Type I Collagen C-telopeptide (sCTX)

    %CfB in sCTX was assessed as part of pharmacodynamics parameter with US-licensed Prolia® was assessed in female participants with postmenopausal osteoporosis.

    Time frame: Weeks 4, 26, 52 and 78

  8. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The safety and tolerability of RGB-14-P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.

    Time frame: Main Period: From screening (Weeks -5 to 0) to Week 52; Transition Period: From Week 52 to Week 78

  9. Number of Participants With Anti-drug Antibodies (ADAs)

    Number of participants with positive ADAs was assessed.

    Time frame: Weeks 0, 2, 4, 26, 28, 30, 52, 54, 56 and 78

  10. Number of Participants With Neutralizing Antibodies

    Number of participants with positive neutralizing antibodies was assessed.

    Time frame: Weeks 0, 2, 4, 26, 28, 30, 52, 54, 56 and 78

  11. Titre of ADAs

    The immunogenicity of RGB -14- P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.

    Time frame: Weeks 0, 2, 4, 26, 28, 30, 52, 54, 56 and 78

07

Results

Posted Oct 24, 2024

Participant flow

The study was conducted between 21-September-2021 (first subject first visit) to 15-November-2023 (last subject last visit).

Main Period (Week 0 to Week 52)
Participant flow — Main Period (Week 0 to Week 52)
MilestoneMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Started242231000
Completed225211000
Not completed1720000
Withdrew: Withdrawal by subject813000
Withdrew: Adverse event22000
Withdrew: Lost to follow-up30000
Withdrew: Protocol deviation10000
Withdrew: Death01000
Withdrew: Subject's personal reason02000
Withdrew: Exclusion criteria met10000
Withdrew: Study objective confounded by monoclonal gammopathy10000
Withdrew: Other12000
Transition Period (Week 52 to Week 78)
Participant flow — Transition Period (Week 52 to Week 78)
MilestoneMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Started00636263
Completed00636262
Not completed00001
Withdrew: Withdrawal by subject00001

Outcome measures

PrimaryPercentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD)

Percentage change from baseline in lumbar bone BMD was assessed. BMD at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). This outcome measure was assessed for main period.

Time frame:
Week 52
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD)
Percentage change from baselineMain Period: RGB-14-PMain Period: Prolia®
Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD)5.68 ± 3.5355.19 ± 4.118
Statistical analysis
  • Main Period: RGB-14-P vs Main Period: Prolia® · ANCOVA · Estimated difference: 0.18 · 90% CI -0.465 to 0.826
  • Main Period: RGB-14-P vs Main Period: Prolia® · ANCOVA · Estimated difference: 0.55 · 90% CI -0.099 to 1.191
PrimaryArea Under the Effective Curve (AUEC) After the First Dose Until Day 183 of %CfB in Serum Type I Collagen C-telopeptide (sCTX)

The AUEC of %CfB in sCTX of RGB-14-P was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants was demonstrated with postmenopausal osteoporosis. This outcome measure was assessed for main period only.

Time frame:
Week 26
Reported as:
Mean · mg/dL*day
Area Under the Effective Curve (AUEC) After the First Dose Until Day 183 of %CfB in Serum Type I Collagen C-telopeptide (sCTX)
mg/dL*dayMain Period: RGB-14-PMain Period: Prolia®
Area Under the Effective Curve (AUEC) After the First Dose Until Day 183 of %CfB in Serum Type I Collagen C-telopeptide (sCTX)14609.67 ± 3142.08614134.86 ± 7331.714
Statistical analysis
  • Main Period: RGB-14-P vs Main Period: Prolia® · ANCOVA · p = 0.494 · Geometric mean ratio: 1.01 · 95% CI 0.978 to 1.046
Secondary%CfB in Total Hip BMD

%CfB in total hip BMD was assessed.

Time frame:
Weeks 26, 52 and 78
Reported as:
Mean · Percentage change from baseline
%CfB in Total Hip BMD
Percentage change from baselineMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 262.42 ± 2.6592.69 ± 2.5192.46 ± 2.7122.81 ± 2.6073.35 ± 2.559
Week 523.42 ± 2.9163.49 ± 2.8723.03 ± 3.1033.36 ± 2.6964.21 ± 3.452
Week 78——4.24 ± 3.3814.12 ± 3.1284.95 ± 3.849
Statistical analysis
  • Main Period: RGB-14-P vs Main Period: Prolia® · Mixed model repeated measures · p = 0.199 · Estimated difference: -0.31 · 95% CI -0.792 to 0.165
  • Main Period: RGB-14-P vs Main Period: Prolia® · mixed model repeated measures · p = 0.543 · Estimated difference: -0.16 · 95% CI -0.680 to 0.358
Secondary%CfB in Lumbar Spine BMD

%CfB in lumbar spine BMD was assessed.

Time frame:
Weeks 26 and 78
Reported as:
Mean · Percentage change from baseline
%CfB in Lumbar Spine BMD
Percentage change from baselineMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 263.56 ± 3.7473.45 ± 4.2273.98 ± 3.1853.39 ± 3.8483.68 ± 4.979
Week 78——7.03 ± 3.8287.06 ± 4.3277.09 ± 4.240
Statistical analysis
  • Main Period: RGB-14-P vs Main Period: Prolia® · mixed model for repeated measures · p = 0.929 · Estimated difference: 0.03 · 95% CI -0.703 to 0.769
Secondary%CfB in Femoral Neck BMD

%CfB in femoral neck BMD was assessed by DXA.

Time frame:
Weeks 26, 52 and 78
Reported as:
Mean · Percentage change from baseline
%CfB in Femoral Neck BMD
Percentage change from baselineMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 261.88 ± 3.0401.94 ± 3.6101.60 ± 2.8332.21 ± 3.2962.35 ± 4.057
Week 522.42 ± 3.6872.64 ± 3.7511.95 ± 3.6212.60 ± 3.1273.24 ± 4.549
Week 78——3.08 ± 4.2593.06 ± 3.3374.04 ± 4.764
SecondaryNumber of Participants With Vertebral Fragility Fracture

Number of participants with vertebral fragility fracture was assessed. Information on vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.

Time frame:
Weeks 52 and 78
Reported as:
Count of participants · Participants
Number of Participants With Vertebral Fragility Fracture
ParticipantsMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 5248———
Week 78——342
SecondaryNumber of Participants With Non-vertebral Fragility Fracture

Number of participants with non-vertebral fragility fracture was assessed. Information on non-vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.

Time frame:
Weeks 52 and 78
Reported as:
Count of participants · Participants
Number of Participants With Non-vertebral Fragility Fracture
ParticipantsMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 52410———
Week 78——253
Secondary%CfB in Serum Procollagen Type 1 N Terminal Propeptide (P1NP)

%CfB in serum P1NP was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants with postmenopausal osteoporosis.

Time frame:
Weeks 4, 26, 52 and 78
Reported as:
Mean · Percentage change from baseline
%CfB in Serum Procollagen Type 1 N Terminal Propeptide (P1NP)
Percentage change from baselineMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 422.10 ± 14.90520.22 ± 15.09119.85 ± 13.93918.45 ± 15.83517.31 ± 15.524
Week 2665.92 ± 17.82862.89 ± 29.29468.42 ± 11.69363.41 ± 42.67766.08 ± 16.098
Week 5265.04 ± 19.13163.82 ± 21.71264.86 ± 16.90266.05 ± 20.42865.89 ± 17.651
Week 78——64.12 ± 18.84566.91 ± 16.81663.08 ± 21.364
Secondary%CfB in Serum Type I Collagen C-telopeptide (sCTX)

%CfB in sCTX was assessed as part of pharmacodynamics parameter with US-licensed Prolia® was assessed in female participants with postmenopausal osteoporosis.

Time frame:
Weeks 4, 26, 52 and 78
Reported as:
Mean · Percentage change from baseline
%CfB in Serum Type I Collagen C-telopeptide (sCTX)
Percentage change from baselineMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 485.87 ± 9.56785.38 ± 15.50184.96 ± 11.20684.71 ± 23.07188.08 ± 5.832
Week 2669.74 ± 23.21261.51 ± 83.76467.29 ± 23.57253.23 ± 147.67971.27 ± 17.483
Week 5262.90 ± 28.99558.26 ± 63.92760.41 ± 31.95853.89 ± 94.85366.79 ± 24.151
Week 78——58.70 ± 34.11753.32 ± 42.85557.38 ± 30.562
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

The safety and tolerability of RGB-14-P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.

Time frame:
Main Period: From screening (Weeks -5 to 0) to Week 52; Transition Period: From Week 52 to Week 78
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Any AE161158000
Any TEAEs158152302525
Any TEAEs severe or worse severity89010
Any treatment related TEAE3632251
Any treatment related TEAE severe or worse severity10000
Any serious TEAEs716000
Any serious TEAEs severe or worse severity59000
Any non-serious TEAEs158149302525
Any AEs leading to participant discontinuation23000
Any TEAEs leading to subject discontinuation23000
Any treatment related TEAE leading to participant discontinuation10000
Any TEAEs leading to discontinuation of IMP22000
Any treatment related TEAE leading to discontinuation of IMP10000
Any fracture TEAE918431
Any fracture TEAE severe or worse severity21000
Any serious fracture TEAEs11000
Any serious fracture TEAEs severe or worse severity11000
Deaths01000
Any AE leading to death01000
Any TEAE leading to death01000
Any injection site reactions02031
Any treatment related serious TEAE00000
Any treatment related serious TEAE severe or worse severity00000
Any treatment related fracture TEAE00000
Any treatment related fracture TEAE severe or worse severity00000
Any treatment related serious fracture TEAE00000
Any treatment related serious fracture TEAE severe or worse severity00000
Any treatment related fatal serious TEAEs00000
Any injection site reactions of CTCAE grade ≥ 300000
Any injection site reactions severe or worse severity00000
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs)

Number of participants with positive ADAs was assessed.

Time frame:
Weeks 0, 2, 4, 26, 28, 30, 52, 54, 56 and 78
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs)
ParticipantsMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 001000
Week 220000
Week 400000
Week 2600000
Week 2801001
Week 3001001
Week 5200000
Week 54——001
Week 56——001
Week 78——000
SecondaryNumber of Participants With Neutralizing Antibodies

Number of participants with positive neutralizing antibodies was assessed.

Time frame:
Weeks 0, 2, 4, 26, 28, 30, 52, 54, 56 and 78
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibodies
ParticipantsMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 0—0———
Week 21————
Week 28—1——1
Week 30—0——0
Week 54————1
Week 56————1
SecondaryTitre of ADAs

The immunogenicity of RGB -14- P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.

Time frame:
Weeks 0, 2, 4, 26, 28, 30, 52, 54, 56 and 78
Reported as:
Median · Titre
Titre of ADAs
TitreMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Week 0NA (NA to NA)302.0 (302 to 302)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Week 2761.0 (60 to 1462)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Week 4NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Week 26NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Week 28NA (NA to NA)172.0 (172 to 172)NA (NA to NA)NA (NA to NA)172.0 (172 to 172)
Week 30NA (NA to NA)211.0 (211 to 211)NA (NA to NA)NA (NA to NA)211.0 (211 to 211)
Week 52NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Week 54——NA (NA to NA)NA (NA to NA)224.0 (224 to 224)
Week 56——NA (NA to NA)NA (NA to NA)152.0 (152 to 152)
Week 78——NA (NA to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over Main Period: From screening (Weeks -5 to 0) to Week 52; Transition Period: From Week 52 to Week 78. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Period: RGB-14-P0/242 (0%)7/242 (2.9%)100/242 (41.3%)
Main Period: Prolia®1/231 (0.4%)16/231 (6.9%)85/231 (36.8%)
Transition Period: RGB-14-P to RGB-14-P0/63 (0%)0/63 (0%)4/63 (6.3%)
Transition Period: Prolia® to RGB-14-P0/62 (0%)0/62 (0%)3/62 (4.8%)
Transition Period: Prolia® to Prolia®0/63 (0%)0/63 (0%)6/63 (9.5%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
Meniscus injuryInjury, poisoning and procedural complications1/2421/2310/630/620/63
Radius fractureInjury, poisoning and procedural complications0/2421/2310/630/620/63
Tendon ruptureInjury, poisoning and procedural complications0/2421/2310/630/620/63
Muscular weaknessMusculoskeletal and connective tissue disorders0/2421/2310/630/620/63
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/2421/2310/630/620/63
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2421/2310/630/620/63
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2421/2310/630/620/63
Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2421/2310/630/620/63
Follicular lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2421/2310/630/620/63
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2421/2310/630/620/63
Most frequent other events
Most frequent other events
EventMain Period: RGB-14-PMain Period: Prolia®Transition Period: RGB-14-P to RGB-14-PTransition Period: Prolia® to RGB-14-PTransition Period: Prolia® to Prolia®
COVID-19Infections and infestations25/24224/2310/630/620/63
HypocalcaemiaMetabolism and nutrition disorders22/24222/2313/631/622/63
NasopharyngitisInfections and infestations23/24221/2311/632/624/63
Upper respiratory tract infectionInfections and infestations23/24211/2310/630/620/63
HeadacheNervous system disorders14/2424/2310/630/620/63
HypertensionVascular disorders8/24213/2310/630/620/63
ArthralgiaMusculoskeletal and connective tissue disorders12/24210/2310/630/620/63
Urinary tract infectionInfections and infestations11/24211/2310/630/620/63

Baseline characteristics

The full analysis set (FAS) comprised all participants to whom the investigational medicinal product (IMP) has been randomized. Main period.

Age, Continuous
Age, Continuous(Years)Main Period: RGB-14-PMain Period: Prolia®Total
Mean66.7 ± 5.2066.8 ± 4.9166.7 ± 5.06
Sex: Female, Male
Sex: Female, Male(Participants)Main Period: RGB-14-PMain Period: Prolia®Total
Female242231473
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Period: RGB-14-PMain Period: Prolia®Total
Hispanic or Latino182240
Not Hispanic or Latino223209432
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Period: RGB-14-PMain Period: Prolia®Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American022
White241229470
More than one race000
Unknown or Not Reported000
08

Study locations

59 sites
  • Global Health Research Center
    Miami Lakes, Florida 33016, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Excel Clinical Research - Internal Medicine
    Las Vegas, Nevada 89109, United States
  • Medical Center Hera EOOD - Rheumatology Office
    Sofia, Sofia-Grad 1510, Bulgaria
  • Medical Center Medconsult Pleven
    Pleven, 5803, Bulgaria
  • UMHAT Kaspela
    Plovdiv, 4001, Bulgaria
  • DKC "Sveti Georgi"
    Plovdiv, 4002, Bulgaria
  • UMHAT Kaspela (Endocrinology/metabolic disease)
    Plovdiv, 4002, Bulgaria
  • UMHAT Pulmed - Reumathology
    Plovdiv, 4002, Bulgaria
  • UMHAT Plovdiv
    Plovdiv, Bulgaria
  • Medical Center - Teodora EOOD
    Ruse, Bulgaria
  • Medical Center Excelsior
    Sofia, 1407, Bulgaria
  • "DCC XVII-Sofia" EOOD
    Sofia, 1505, Bulgaria
  • APAVAR Lekarna
    Ostrava, Ostrava-město 702 00, Czechia
  • FN Hradec Kralove
    Hradec Králové, 500 05, Czechia
  • Klatovska nemocnice, a.s.
    Klatovy, 339 01, Czechia
  • Fakultni nemocnice Plzen
    Plzen, Czechia
  • Affidea Praha s.r.o.
    Praha 11, 148 00, Czechia
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 305 99, Czechia
  • BAZM KKH EOK Szt Ferenc Tagkh
    Miskolc, Borsod-Abaúj-Zemplén 3529, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Qualiclinic Kft.
    Budapest, 1036, Hungary
  • Semmelweis Egyetem
    Budapest, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Csongrad Megyei Dr Bugyi Istvan Korhaz
    Szentes, 6600, Hungary
  • IRCCS Policlinico San Matteo, Università degli studi di Pavi
    Pavia, 27100, Italy
  • Azienda Ospedaliera di Perugia - Ospedale Santa Maria della
    Perugia, 06125, Italy
  • Azienda Ospedaliero Universitaria Integrata Verona
    Veneto, 37126, Italy
  • Zespol Poradni Specjalistycznych REUMED, Filia nr 1 Wallenroda
    Lublin, Lubelskie 20-607, Poland
  • Lubelskie Centrum Diagnostyczne
    Świdnik, Lubelskie 21-040, Poland
  • Barbara Rewerska Diamond Clin.
    Krakow, Malopolskie 31-559, Poland
  • Centralny Szpital Kliniczny MSWiA w Warszawie
    Warszawa, Mazowieckie 02-507, Poland
  • Nasz Lekarz Osrodek Badan Klinicznych
    Bialystok, Podlaskie 15-082, Poland
  • ClinicMed Daniluk, Nowak Sp. J
    Bialystok, Podlaskie 15-879, Poland
  • Komisja Bioetyczna przy OIL w Bialymstoku
    Białystok, Podlaskie 15-082, Poland
  • Nasz Lekarz Osrodek Badan Klinicznych
    Bydgoszcz, 85-065, Poland
  • Centrum Medyczne Pratia Gdynia
    Gdynia, 81-338, Poland
  • Centrum Medyczne Pratia Katowice
    Katowice, 40-081, Poland
  • Centrum Medyczne Plejady
    Kraków, 30-363, Poland
  • Oswiecimskie Centrum Badan Klinicznych
    Oswiecim, 32-600, Poland
  • RCMed Oddzial Sochaczew
    Sochaczew, 96-500, Poland
  • RCMed
    Sochaczew, 96-500, Poland
  • Medycyna Kliniczna
    Warszawa, 00-874, Poland
  • RCMed Oddział Warszawa
    Warszawa, 00-892, Poland
  • Centrum Medyczne Reuma Park
    Warszawa, 02-691, Poland
  • H. Ntra. Sra. de la Esperanza
    Santiago De Compostela, A Coruña 15705, Spain
  • Corporacio Sanitaria Parc Tauli de Sabadell - Servicio de reumatologia
    Sabadell, Barcelona 08208, Spain
  • Complejo Hospitalario Universitario A Coruña
    A Coruña, 15006, Spain
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Centro Medico Instituto Palacios
    Madrid, 28009, Spain
  • Clinica Gaias Santiago
    Santiago De Compostela, 15703, Spain
  • Medychnyi tsentr tovarystva z obmezhenoyu vidpovidalnistyu "Medbud-Klinik"
    Kyiv, Kyïv 0 3037, Ukraine
  • Derzhavna ustanova "Instytut herontolohii imeni D.F. Chebotarova Natsionalnoi akademii medychnykh nauk Ukrainy
    Kyiv, Kyïv 04114, Ukraine
  • Vinnytska oblasna klinichna likarnia im. M.I. Pyrohova
    Vinnytsia, Vinnyts'ka Oblast' 21018, Ukraine
  • Naukovo-doslidnyi instytut reabilitatsii osib z invalidnistiu (navchalno-naukovo-likuvalnyi kompleks) Vinnytskoho natsionalnoho medychnoho universytetu im. M.I. Pyrohova
    Vinnytsia, Vinnyts'ka Oblast' 21029, Ukraine
  • Kyivska klinichna likarnia na zaliznychnomu transporti #2 filii "Tsentr okhorony zdoroviya" AT "Ukrayinska Zaliznytsia"
    Kyïv, 03049, Ukraine
  • Med tsentr TOV "Tsentr simeinoi medytsyny plius"
    Kyïv, 04210, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2023, 24 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 24 months is close to that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2021
First posted
Oct 21, 2021
StartActual
Sep 21, 2021
Primary completionActual
Oct 2, 2023
CompletionActual
Nov 15, 2023
Results first posted
Oct 24, 2024
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05087030
Lead sponsor
Gedeon Richter Plc.
Responsible party
Sponsor
First posted
Oct 21, 2021
Start date
Sep 21, 2021
Primary completion
Oct 2, 2023
Completion
Nov 15, 2023
Results posted
Oct 24, 2024
Last update
Oct 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion